Biomarkers for targeted therapies

Efficient tools to Novel targeted therapies offer promise in improving patient outcomes, notably in the context of cancer. However, it is crucial to identify which patients will benefit from targeted therapy. Biomarkers to predict or monitor therapy response are becoming essential.

Predictive biomarkers offer significant benefit by refining the treated population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. This new concept is the Personalized Medicine.

Personalized Medicine aims to achieve optimum medical outcomes in the management of patient's diseases by using molecular analysis. In this quest, AnyGenes® developed a novel approach based on combined biomarker's pathways analysis thanks to it own SignArrays® system. Many targeted therapies are being studied in clinical trials, and many more are in preclinical testing (research studies in vitro or with animals).

To Accelerate and Improve Targeted Therapies Development, AnyGenes® can provide qPCR arrays-focused pathways (SignArrays®), built specifically for each targeted therapy. Therefore, AnyGenes® can also help to identify the most efficient biomarkers combination with analytically and clinically validated assays.

AnyGenes® provides clinicians with validated biomarkers assays to monitor targeted therapies response.

Malignant Melanoma Case
  • 50 - 60% of malignant melanomas have an activating BRAF mutation (V600).
  • Therapies targeting BRAF have been validated but despite promising results, the presence of many primary and acquired resistance cases complicates the patient care.
  • To respond to strong clinical need, AnyGenes’ aim is to develop companion tests in order to directly identify the best drug combination for each patient.
Tentori et al. Challenging resistance mechanisms to therapies for metastatic melanoma Cell Press
Trends in Pharmacological Sciences Dec 2013, Vol. 34, No. 12
For more information, please contact us.